Drug Safety
1 month 1 week ago
Slick poster, but must be careful w/real world data. Big risk of confounding/channeling bias
Pts with MACE risk (not always well-characterized by ICD codes) also less likely to receive JAK & therefore less liekly to have subsequent MACE
#ACR24 @RheumNow Abstr#1394 https://t.co/lilU0byJ1s
1 month 1 week ago
Getting more data on using deucravacitinib for PsO/PsA manifestations
Impressive effect on scalp psoriasis (which often means a lot to patients)
Given how safe it is, it's increasingly tempting to use more of it in mild-mod PsA
#ACR24 PSORIATYK SCALP trial ABST1137 @RheumNow https://t.co/vxS3RSlIN0
1 month 1 week ago
What do current national/international rheumatology association guidelines say about perioperative discontinuation of biologics?
it's highly, highly variable
no wonder people get confused!
#ACR24 ABST1037 @CatherineL_Hill @RheumNow https://t.co/cmJ3qKU1QT
1 month 1 week ago
Serrano-Combarro et al. Case series of upadacitinib in RA-ILD. 18 patients. Report stable/improved dyspnoea and HRCT over 12 months. PFTs shown, relatively stable @RheumNow #ACR24 Abstr#1372 https://t.co/yncy0lPq60 https://t.co/mrDMtEDwUt
1 month 1 week ago
Great table re:side effects of even low dose steroids in RA
Likely generalizes to other diseases ie PMR, SLE
P in prednisone stands for poison!
#ACR24 @RheumNow https://t.co/0opDEtzm9E
1 month 1 week ago
Petri recommends IM triamcinolone as safer than prednisone dosing per FLOAT trial, decreased risk of fx
@RheumNow #ACR24
@jhrheumatology https://t.co/vhMRdSkBAA https://t.co/novlGcss6x
1 month 1 week ago
Late-onset asthma but earlier EGPA diagnosis?
Abstract 1604 used IQVIA data to develop a machine learning model for better EGPA dx. Key predictors included eosinophilia, asthma, chronic sinusitis, multiple CXRs, skin biopsies, and GC prescriptions. @RheumNow #ACR24
1 month 1 week ago
Sukumaran et al. Does does of IA steroid matter in knee injection? RCT 30 patients. Triamcinolone. 6-week WOMAC decrease 6% in 10mg, 10% in 20mg , 29% in 40mg @RheumNow #ACR24 Abstr#1186 https://t.co/WUYiEP5dSo
1 month 1 week ago
Exciting early data for new highly selective TYK2i zasocitinib
Improved PASI skin scores (though not as much as IL23i...)
Funky skin-related adverse events at higher doses, not sure what to make of that?
#ACR24 @rheumnow Abstr#1477 https://t.co/CtOFsoHdBh